Page last updated: 2024-10-31

nadifloxacin and Exanthem

nadifloxacin has been researched along with Exanthem in 2 studies

nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source

Research Excerpts

ExcerptRelevanceReference
"Severe exanthema (grade III/IV) develops in about 9-19 % of patients with the necessity of cetuximab dose reduction or cessation."1.39Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. ( Berger, MR; Galle, PR; Gockel, I; Graf, C; Herzog, J; Lang, H; Möhler, M; Schimanski, CC; Theobald, M; Wehler, TC, 2013)
"Characteristic papulopustular exanthemas, often described as acneiform rashes, are the most frequent adverse effect associated with this class of novel cancer drugs and develop in > 90% of patients."1.38Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients. ( Bölke, E; Budach, W; Buhren, BA; Eames, T; Ehmann, LM; Gerber, PA; Hetzer, S; Homey, B; Matuschek, C; Meller, S; Schrumpf, H; Wollenberg, A, 2012)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Wehler, TC1
Graf, C1
Möhler, M1
Herzog, J1
Berger, MR1
Gockel, I1
Lang, H1
Theobald, M1
Galle, PR1
Schimanski, CC1
Gerber, PA1
Meller, S1
Eames, T1
Buhren, BA1
Schrumpf, H1
Hetzer, S1
Ehmann, LM1
Budach, W1
Bölke, E1
Matuschek, C1
Wollenberg, A1
Homey, B1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized Control Trial to Compare Doxycycline to Isotretinoin for the Treatment of Acneiform Eruptions in Cancer Patients on Tyrosine Kinase Inhibitors[NCT04864717]Phase 498 participants (Anticipated)Interventional2021-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Other Studies

2 other studies available for nadifloxacin and Exanthem

ArticleYear
Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective.
    Journal of cancer research and clinical oncology, 2013, Volume: 139, Issue:10

    Topics: Administration, Oral; Administration, Topical; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antibo

2013
Management of EGFR-inhibitor associated rash: a retrospective study in 49 patients.
    European journal of medical research, 2012, Feb-23, Volume: 17

    Topics: Administration, Topical; ErbB Receptors; Exanthema; Fluoroquinolones; Humans; Isotretinoin; Mometaso

2012